Канал: POTELIGEO® (mogamulizumab-kpkc)

Lynn's Journey: Mycosis Fungoides (patient)

Lynn's Journey: Mycosis Fungoides (patient)

EXPERT PERSPECTIVES: Diagnosis

EXPERT PERSPECTIVES: Diagnosis

Lannie’s Journey: Sézary Syndrome (patient)

Lannie’s Journey: Sézary Syndrome (patient)

Jeff's Journey: Mycosis Fungoides (patient)

Jeff's Journey: Mycosis Fungoides (patient)

Jim's Journey: Sézary Syndrome (patient)

Jim's Journey: Sézary Syndrome (patient)

Jeffrey's Journey: Sézary Syndrome (patient)

Jeffrey's Journey: Sézary Syndrome (patient)

EXPERT PERSPECTIVES: Patient Monitoring & Adherence

EXPERT PERSPECTIVES: Patient Monitoring & Adherence

Kyowa Kirin Cares Connect The Dots

Kyowa Kirin Cares Connect The Dots

Long-term Safety Follow-up

Long-term Safety Follow-up

POTELIGEO Efficacy in Blood

POTELIGEO Efficacy in Blood

POTELIGEO Efficacy in Skin

POTELIGEO Efficacy in Skin

How POTELIGEO Uniquely Targets CCR4

How POTELIGEO Uniquely Targets CCR4

The MAVORIC Trial Patient Population

The MAVORIC Trial Patient Population

POTELIGEO and the CCR4 Target

POTELIGEO and the CCR4 Target

POTELIGEO Mechanism of Action

POTELIGEO Mechanism of Action

POTELLIGENT® Technology

POTELLIGENT® Technology

The POTELIGEO Infusion Process

The POTELIGEO Infusion Process

EXPERT PERSPECTIVES: Disease Progression and Patient Management

EXPERT PERSPECTIVES: Disease Progression and Patient Management

EXPERT PERSPECTIVES: Treatment Considerations

EXPERT PERSPECTIVES: Treatment Considerations

EXPERT PERSPECTIVES: Patient Communication

EXPERT PERSPECTIVES: Patient Communication

EXPERT PERSPECTIVES: The MAVORIC Trial

EXPERT PERSPECTIVES: The MAVORIC Trial

EXPERT PERSPECTIVES: Patient Identification

EXPERT PERSPECTIVES: Patient Identification

Important Safety Information for Patients

Important Safety Information for Patients

Indication and Important Safety Information

Indication and Important Safety Information